Research on neurodegenerative diseases including Alzheimer's, Parkinson's, ALS, and Huntington's disease

From November 2025

CCKBR-Gs and -Gq signaling beneficial for Alzheimer's treatment, ref: Wang doi.org/10.1016/j.cell.2025.10.034/
Lecanemab activates microglial functions for amyloid clearance in Alzheimer's, ref: Albertini doi.org/10.1038/s41593-025-02125-8/
Higher physical activity linked to slower cognitive decline in Alzheimer's, ref: Yau doi.org/10.1038/s41591-025-03955-6/
Plasma TDP-43 correlates with brain TDP-43 burden in Alzheimer's, ref: Wang doi.org/10.1186/s13024-025-00910-4/
Lifetime risk of MCI increases with amyloid PET severity, ref: Jack doi.org/10.1016/S1474-4422(25)00350-3/
Blood biomarkers predict transitions from normal cognition to dementia, ref: Valletta doi.org/10.1038/s41467-025-66728-2/
Obstructive sleep apnea linked to increased Parkinson's disease risk, ref: Neilson doi.org/10.1001/jamaneurol.2025.4691/
TDP-43 mis-splicing contributes to neuronal hyperexcitability in ALS, ref: Joseph doi.org/10.1038/s41593-025-02096-w/

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec